Prostate cancer is the most frequent epithelial neoplasia after skin cancer in men starting from 50 years and prostate-specific antigen (PSA) dosage can be used as an early screening tool. Prostate cancer imaging includes several radiological modalities, ranging from ultrasonography, computed tomography (CT), and magnetic resonance to nuclear medicine hybrid techniques such as single-photon emission computed tomography (SPECT)/CT and positron emission tomography (PET)/CT. Innovation in radiopharmaceutical compounds has introduced specific tracers with diagnostic and therapeutic indications, opening the horizons to targeted and very effective clinical care for patients with prostate cancer. The aim of the present review is to illustrate the current knowledge and future perspectives of nuclear medicine, including stand-alone diagnostic techniques and theragnostic approaches, in the clinical management of patients with prostate cancer from initial staging to advanced disease.
前列腺癌是50岁以上男性中仅次于皮肤癌的最常见上皮性肿瘤，前列腺特异性抗原（PSA）检测可作为早期筛查工具。前列腺癌影像学检查涵盖多种放射学模式，包括超声、计算机断层扫描（CT）、磁共振成像以及核医学融合技术，如单光子发射计算机断层扫描（SPECT）/CT和正电子发射断层扫描（PET）/CT。放射性药物化合物的创新引入了具有诊断和治疗适应症的特定示踪剂，为前列腺癌患者开启了靶向高效临床诊疗的新视野。本综述旨在阐述核医学在前列腺癌临床管理中的现有认知与未来展望，涵盖从初始分期到晚期疾病的独立诊断技术与诊疗一体化策略。
Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives
肿瘤(癌症)患者之家